Recombinant adeno-associated virus vectors
AssigneeRhone-Poulenc Rorer Pharmaceuticals Inc.
InventorsJane S. Lebkowski, Maureen A. McNally, Thomas B. Okarma
Life of this patent
Estimating the term…
Abstract
Simplified methods to produce recombinant adeno-associated virus (rAAV) vectors are described. The AAV rep and cap genes are combined in a single recombinant adenovirus vector, i.e., a rep/cap adenovirus vector which combines in a single vector all complementing functions required for rAAV production. The rep/cap vectors of the present invention comprise: genes encoding helper functions, preferably from adenovirus, sufficient to permit AAV replication; and AAV cap and rep genes. In adenovirus rep/cap vectors the rep and cap genes may, for example, replace the adenovirus E3 gene or the adenovirus E1a and E1b genes.
Claims8
A rep/cap vector, wherein said vector is a recombinant adenovirus or herpes virus which comprises adeno-associated virus rep and cap genes, and said adenovirus or herpes virus retains helper functions sufficient to permit adeno-associated virus replication.
A rep/cap adenovirus vector, wherein said vector is a recombinant adenovirus comprising adeno-associated virus rep and cap genes, and said adenovirus retains helper functions sufficient to permit adeno-associated virus replication.
A rep/cap adenovirus vector, wherein said vector is a recombinant adenovirus comprising adeno-associated virus rep and cap genes replacing the adenovirus E1a and E1b genes, and said adenovirus vector retains helper functions sufficient to permit adeno-associated virus replication in the presence of adenovirus E1a and E1b gene products.
Dependencies are inferred from the claim text.